<Suppliers Price>

DOTA Zoledronate

Names

[ CAS No. ]:
1908409-18-6

[ Name ]:
DOTA Zoledronate

[Synonym ]:
2,2',2''-{10-[2-({2-[1-(2-Hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl]ethyl}amino)-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl}triacetic acid
1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[1-(2-hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl]ethyl]amino]-2-oxoethyl]-

Biological Activity

[Description]:

DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Others >> Others

[In Vitro]

DOTA-Zoledronate is a promising agent for the development of other future-oriented radionuclide therapy concepts for personalized nuclear oncology[1].

[References]

[1]. The ITM Group Announces In-Licensing of DOTA-Zoledronate Theranostic Agent.

Chemical & Physical Properties

[ Density]:
1.7±0.1 g/cm3

[ Molecular Formula ]:
C23H41N7O14P2

[ Molecular Weight ]:
701.56

[ Exact Mass ]:
701.218689

[ LogP ]:
-3.89

[ Index of Refraction ]:
1.670

Related Compounds